US20260108574A1 Herbal Composition for Metabolic Disorders
Summary
The USPTO has published patent application US20260108574A1, filed October 16, 2025 by M/S Natural and Essential Oils Private Limited, disclosing a herbal composition for treating metabolic disorders in mammals including central obesity, high blood pressure, high blood sugar, stress-induced fatigue, and type 2 diabetes. The composition comprises extracts of Dolichos lablab, Achyranthes aspera, and Cinnamomum zeylanicum or Cinnamomum cassia, standardized to contain proanthocyanidins, saponins, polyphenols, and tannins. The application describes methods of preparation and therapeutic effects including enhanced adiponectin and HDL levels.
“A herbal composition for the treatment of a variety of metabolic disorders in mammals, especially human beings, is disclosed.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
The USPTO published patent application US20260108574A1, disclosing a novel herbal composition for treating a plurality of metabolic disorders including central obesity, high blood pressure, high blood sugar, stress-induced fatigue, and type 2 diabetes. The composition comprises extracts of Dolichos lablab, Achyranthes aspera, and at least one of Cinnamomum zeylanicum and Cinnamomum cassia at predetermined weight ranges, standardized to contain active compounds including proanthocyanidins, saponins, polyphenols, and tannins in predetermined concentration and purity levels.
Affected parties include pharmaceutical companies, drug manufacturers, and healthcare providers researching or developing herbal or botanical therapeutic products for metabolic conditions. This publication establishes a priority date of October 16, 2025 and provides public notice of the applicant's intellectual property claims in this therapeutic space.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
HERBAL COMPOSITION FOR TREATING METABOLIC DISORDERS IN MAMMALS
Application US20260108574A1 Kind: A1 Apr 23, 2026
Assignee
M/S NATURAL AND ESSENTIAL OILS PRIVATE LIMITED
Inventors
ANIRUDH MURTHY RANGA, SAMEER KAMALAKAR AKOLKAR, MELUKOTE SRINIVASA SHETTY MADHUKUMAR
Abstract
A herbal composition for the treatment of a variety of metabolic disorders in mammals, especially human beings, is disclosed. A method of preparing the herbal composition is also disclosed. The herbal composition treats and alleviates a plurality of metabolic disorders, including central obesity, high blood pressure levels, high blood sugar levels, stress-induced fatigue, and type 2 diabetes. The herbal composition comprises the extracts of Dolichos lablab, Achyranthes aspera, and at least one of Cinnamomum zeylanicum and Cinnamomum cassia. The aforementioned extracts are present in the herbal composition at a predetermined weight range. The aforementioned extracts are standardized to contain active compounds, including proanthocyanidins, saponins, polyphenols, and tannins, in a predetermined concentration and in predetermined purity levels. The herbal composition causes an enhancement of adiponectin levels and high-density lipoprotein (HDL) levels, and a reduction in the accumulation of adipose tissue, total cholesterol levels, triglyceride levels, and low-density lipoprotein (LDL) levels.
CPC Classifications
A61K 36/48 A61K 36/21 A61K 36/54 A61P 3/04 A61P 3/06 A61P 25/22
Filing Date
2025-10-16
Application No.
19360002
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.